focus -WSS

focus

author：knowledge 2025-10-02 02:15:56 - browse：1463

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： How dance can help nurses traumatized by Covid

WSS

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

What to expect at HLTH 2023, the health care industry conference

The future of health care in the House

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Histogen: Failed biotech offers rare public look inside

Why Charlie Gard's case is so disturbing to Americans

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

BioMarin wins approval for gene therapy to treat hemophilia A

Histogen: Failed biotech offers rare public look inside

Cancer drug shortages should be causing more outrage

Sana to lay off nearly a third of staff, de

Novavax promises a turnaround & Lilly roils the obesity market

Sanofi seeks simpler, safer CRISPR sickle cell cure

Medical records are filled with copy

Google and Epic fight stronger regulation of AI in health care

Wikipedia

A Q&A with the global head of Boehringer Ingelheim's innovation unit

FDA authorizes Novavax’s updated Covid

WHO calls for emergency meeting on new China virus, as cases spread

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Sana to lay off nearly a third of staff, de

FDA rejects Alnylam's heart disease treatment over insufficient data

entertainment

knowledge

hotspot

focus